Abstract GS1-04: IMpassion130: Efficacy in immune biomarker subgroups from the global, randomized, double-blind, placebo-controlled, phase III study of atezolizumab +nab-paclitaxel in patients with treatment-naïve, locally advanced or metastatic triple-negative breast cancer

Triple Negative ◽

Locally Advanced ◽

Phase Iii ◽

Double Blind ◽

Double Blind Placebo ◽

Treatment Naïve ◽

IMpassion130: Results from a global, randomised, double-blind, phase III study of atezolizumab (atezo) + nab-paclitaxel (nab-P) vs placebo + nab-P in treatment-naive, locally advanced or metastatic triple-negative breast cancer (mTNBC)

Annals of Oncology ◽

10.1093/annonc/mdy424.008 ◽

2018 ◽

Vol 29 ◽

pp. viii707-viii708 ◽

Cited By ~ 3

Author(s):

P. Schmid ◽

S. Adams ◽

H.S. Rugo ◽

A. Schneeweiss ◽

C.H. Barrios ◽

...

Keyword(s):

Breast Cancer ◽

Triple Negative ◽

Locally Advanced ◽

Phase Iii ◽

Double Blind ◽

Treatment Naïve ◽

IMpassion131: Phase III study comparing 1L atezolizumab with paclitaxel vs placebo with paclitaxel in treatment-naive patients with inoperable locally advanced or metastatic triple negative breast cancer (mTNBC)

Annals of Oncology ◽

10.1093/annonc/mdx365.080 ◽

2017 ◽

Vol 28 ◽

pp. v105

Author(s):

D. Miles ◽

F. Andre ◽

J. Gligorov ◽

S. Verma ◽

B. Xu ◽

...

Keyword(s):

Breast Cancer ◽

Triple Negative ◽

Locally Advanced ◽

Phase Iii ◽

Treatment Naïve ◽

Abstract OT1-01-01: IMpassion131: A phase III study comparing 1L atezolizumab with paclitaxel vs placebo with paclitaxel in treatment-naive patients with inoperable locally advanced or metastatic triple negative breast cancer (TNBC)

10.1158/1538-7445.sabcs17-ot1-01-01 ◽

2018 ◽

Cited By ~ 1

Author(s):

D Miles ◽

F André ◽

J Gligorov ◽

S Verma ◽

B Xu ◽

...

Keyword(s):

Breast Cancer ◽

Triple Negative ◽

Locally Advanced ◽

Phase Iii ◽

Treatment Naïve ◽

Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

Annals of Oncology ◽

10.1016/j.annonc.2021.05.801 ◽

2021 ◽

Author(s):

D. Miles ◽

J. Gligorov ◽

F. André ◽

D. Cameron ◽

A. Schneeweiss ◽

...

Keyword(s):

Breast Cancer ◽

Triple Negative ◽

Locally Advanced ◽

Phase Iii ◽

First Line ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo

Abstract GS3-04: Double-blind placebo (PBO)-controlled randomized phase III trial evaluating first-line ipatasertib (IPAT) combined with paclitaxel (PAC) forPIK3CA/AKT1/PTEN-altered locally advanced unresectable or metastatic triple-negative breast cancer (aTNBC): primary results from IPATunity130 Cohort A

10.1158/1538-7445.sabcs20-gs3-04 ◽

2021 ◽

Author(s):

Rebecca Dent ◽

Sung-Bae Kim ◽

Mafalda Oliveira ◽

Carlos Barrios ◽

Joyce O’Shaughnessy ◽

...

Keyword(s):

Breast Cancer ◽

Triple Negative ◽

Locally Advanced ◽

Phase Iii ◽

First Line ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo

LBA15 Primary results from IMpassion131, a double-blind placebo-controlled randomised phase III trial of first-line paclitaxel (PAC) ± atezolizumab (atezo) for unresectable locally advanced/metastatic triple-negative breast cancer (mTNBC)

Annals of Oncology ◽

10.1016/j.annonc.2020.08.2243 ◽

2020 ◽

Vol 31 ◽

pp. S1147-S1148 ◽

Cited By ~ 6

Author(s):

D.W. Miles ◽

J. Gligorov ◽

F. André ◽

D. Cameron ◽

A. Schneeweiss ◽

...

Keyword(s):

Breast Cancer ◽

Triple Negative ◽

Locally Advanced ◽

Phase Iii ◽

First Line ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo

KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo for previously untreated, locally recurrent, inoperable or metastatic triple-negative breast cancer (mTNBC)

Annals of Oncology ◽

10.1093/annonc/mdx656 ◽

2017 ◽

Vol 28 ◽

pp. x25

Author(s):

J. Cortes Castan ◽

Z. Guo ◽

V. Karantza ◽

G. Aktan

Keyword(s):

Breast Cancer ◽

Triple Negative ◽

Phase Iii ◽

Double Blind ◽

Phase Iii Study ◽

Abstract CT069: KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy for previously untreated, locally recurrent, inoperable or metastatic triple-negative breast cancer (mTNBC)

10.1158/1538-7445.am2017-ct069 ◽

2017 ◽

Cited By ~ 1

Author(s):

Javier Cortes ◽

Zifang Guo ◽

Vassiliki Karantza ◽

Gursel Aktan

Keyword(s):

Breast Cancer ◽

Triple Negative ◽

Phase Iii ◽

Double Blind ◽

Phase Iii Study ◽

Faculty Opinions recommendation of KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (PBO) + chemo for previously untreated, locally recurrent, inoperable or metastatic triple-negative breast cancer (mTNBC).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.733209651.793559074 ◽

2019 ◽

Author(s):

Ahmad Awada

Keyword(s):

Breast Cancer ◽

Triple Negative ◽

Phase Iii ◽

Double Blind ◽

Phase Iii Study ◽

KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (PBO) + chemo for previously untreated, locally recurrent, inoperable or metastatic triple-negative breast cancer (mTNBC)

Annals of Oncology ◽

10.1093/annonc/mdx364.016 ◽

2017 ◽

Vol 28 ◽

pp. v72

Author(s):

J. Cortes Castan ◽

Z. Guo ◽

V. Karantza ◽

G. Aktan

Keyword(s):

Breast Cancer ◽

Triple Negative ◽

Phase Iii ◽

Double Blind ◽

Phase Iii Study ◽